{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T18:04:34Z","timestamp":1791396274378,"version":"4.3.3"},"reference-count":56,"publisher":"Xia & He Publishing","issue":"2","license":[{"start":{"date-parts":[[2021,11,19]],"date-time":"2021-11-19T00:00:00Z","timestamp":1637280000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["www.xiahepublishing.com"],"crossmark-restriction":false},"short-container-title":["J Clin Transl Hepatol"],"published-print":{"date-parts":[[2022,4,28]]},"DOI":"10.14218\/jcth.2021.00284","type":"journal-article","created":{"date-parts":[[2021,11,18]],"date-time":"2021-11-18T21:54:55Z","timestamp":1637272495000},"page":"284-296","update-policy":"https:\/\/doi.org\/10.14218\/crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Oncolytic Activity of Wild-type Newcastle Disease Virus HK84 Against Hepatocellular Carcinoma Associated with Activation of Type I Interferon Signaling"],"prefix":"10.14218","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5965-8083","authenticated-orcid":false,"given":"Liming","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5392-3736","authenticated-orcid":false,"given":"Yongdong","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2525-6320","authenticated-orcid":false,"given":"Jiating","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8311-9642","authenticated-orcid":false,"given":"Hong","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoxi","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongmei","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2711-0501","authenticated-orcid":false,"given":"Huachen","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6057-9243","authenticated-orcid":false,"given":"Yi","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"5334","published-online":{"date-parts":[[2021,11,19]]},"reference":[{"key":"key20211118215450_JCTH-D-21-00284-b1","unstructured":"Latest global cancer data: Cancer burden rises to 19.3 million new cases and 10.0 million cancer deaths in 2020. Available from: https:\/\/www.iarc.who.int\/news-events\/latest-global-cancer-data-cancer-burden-rises-to-19-3-million-new-cases-and-10-0-million-cancer-deaths-in-2020\/"},{"issue":"1","key":"key20211118215450_JCTH-D-21-00284-b2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21654","article-title":"Cancer Statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"10125","key":"key20211118215450_JCTH-D-21-00284-b3","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S0140-6736(17)33326-3","article-title":"Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37\u2008513\u2008025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries","volume":"391","author":"Allemani","year":"2018","journal-title":"Lancet"},{"issue":"7","key":"key20211118215450_JCTH-D-21-00284-b4","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/nbt.2287","article-title":"Oncolytic virotherapy","volume":"30","author":"Russell","year":"2012","journal-title":"Nat Biotechnol"},{"key":"key20211118215450_JCTH-D-21-00284-b5","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1002\/1097-0142(196507)18:7<863::AID-CNCR2820180714>3.0.CO;2-V","article-title":"Newcastle disease virus as an antineoplastic agent","volume":"18","author":"Cassel","year":"1965","journal-title":"Cancer"},{"issue":"5","key":"key20211118215450_JCTH-D-21-00284-b6","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1002\/1097-0142(195209)5:5<1025::AID-CNCR2820050518>3.0.CO;2-Q","article-title":"Clinical studies of viruses as antineoplastic agents with particular reference to Egypt 101 virus","volume":"5","author":"Southam","year":"1952","journal-title":"Cancer"},{"key":"key20211118215450_JCTH-D-21-00284-b7","article-title":"Topics in integrative, alternative, and complementary therapies (PDQ\u00ae): health professional version","author":"PDQ Integrative, Alternative, and Complementary Therapies Editorial Board","year":"2002","journal-title":"In: PDQ Cancer Information Summaries. Bethesda (MD): National Cancer Institute (US)"},{"issue":"6","key":"key20211118215450_JCTH-D-21-00284-b8","doi-asserted-by":"crossref","first-page":"201","DOI":"10.3390\/cancers10060201","article-title":"Designer oncolytic adenovirus: coming of age","volume":"10","author":"Baker","year":"2018","journal-title":"Cancers (Basel)"},{"issue":"6","key":"key20211118215450_JCTH-D-21-00284-b9","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.3390\/cancers12061699","article-title":"Optimizing oncolytic viral design to enhance antitumor efficacy: progress and challenges","volume":"12","author":"Chaurasiya","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"12","key":"key20211118215450_JCTH-D-21-00284-b10","doi-asserted-by":"crossref","first-page":"7478","DOI":"10.1128\/JVI.79.12.7478-7491.2005","article-title":"Adenovirus binding to blood factors results in liver cell infection and hepatotoxicity","volume":"79","author":"Shayakhmetov","year":"2005","journal-title":"J Virol"},{"issue":"Pt 12","key":"key20211118215450_JCTH-D-21-00284-b11","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1099\/vir.0.046672-0","article-title":"Vesicular stomatitis virus as a flexible platform for oncolytic virotherapy against cancer","volume":"93","author":"Hastie","year":"2012","journal-title":"J Gen Virol"},{"key":"key20211118215450_JCTH-D-21-00284-b12","doi-asserted-by":"crossref","first-page":"4835","DOI":"10.2147\/IJN.S116447","article-title":"Viruses as nanomedicine for cancer","volume":"11","author":"Badrinath","year":"2016","journal-title":"Int J Nanomedicine"},{"issue":"13","key":"key20211118215450_JCTH-D-21-00284-b13","doi-asserted-by":"crossref","first-page":"16479","DOI":"10.18632\/oncotarget.7660","article-title":"A cancer-favoring oncolytic vaccinia virus shows enhanced suppression of stem-cell like colon cancer","volume":"7","author":"Yoo","year":"2016","journal-title":"Oncotarget"},{"issue":"3","key":"key20211118215450_JCTH-D-21-00284-b14","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.ymthe.2006.05.008","article-title":"Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF","volume":"14","author":"Kim","year":"2006","journal-title":"Mol Ther"},{"issue":"3","key":"key20211118215450_JCTH-D-21-00284-b15","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/sj.cgt.7700431","article-title":"Clinical trial of E1B-deleted adenovirus (dl1520) gene therapy for hepatocellular carcinoma","volume":"9","author":"Habib","year":"2002","journal-title":"Cancer Gene Ther"},{"key":"key20211118215450_JCTH-D-21-00284-b16","unstructured":"News GEB. Pexa-Vec\/Nexavar combination fails Phase III trial in liver cancer 2019. Available from: https:\/\/www.genengnews.com\/news\/pexa-vec-nexavar-combination-fails-phase-iii-trial-in-liver-cancer\/"},{"issue":"6","key":"key20211118215450_JCTH-D-21-00284-b17","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S1470-2045(08)70107-4","article-title":"Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial","volume":"9","author":"Park","year":"2008","journal-title":"Lancet Oncol"},{"issue":"11","key":"key20211118215450_JCTH-D-21-00284-b18","doi-asserted-by":"crossref","first-page":"3350","DOI":"10.1172\/JCI32727","article-title":"Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963","volume":"117","author":"Thorne","year":"2007","journal-title":"J Clin Invest"},{"issue":"3","key":"key20211118215450_JCTH-D-21-00284-b19","doi-asserted-by":"crossref","first-page":"66","DOI":"10.3390\/biomedicines7030066","article-title":"Breaking therapy resistance: an update on oncolytic newcastle disease virus for improvements of cancer therapy","volume":"7","author":"Schirrmacher","year":"2019","journal-title":"Biomedicines"},{"issue":"3","key":"key20211118215450_JCTH-D-21-00284-b20","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3390\/biomedicines4030016","article-title":"Fifty years of clinical application of newcastle disease virus: time to celebrate!","volume":"4","author":"Schirrmacher","year":"2016","journal-title":"Biomedicines"},{"key":"key20211118215450_JCTH-D-21-00284-b21","doi-asserted-by":"crossref","first-page":"15011","DOI":"10.1038\/mto.2015.11","article-title":"Oncolysis by paramyxoviruses: multiple mechanisms contribute to therapeutic efficiency","volume":"2","author":"Matveeva","year":"2015","journal-title":"Mol Ther Oncolytics"},{"issue":"17","key":"key20211118215450_JCTH-D-21-00284-b22","doi-asserted-by":"crossref","first-page":"8285","DOI":"10.1158\/0008-5472.CAN-07-1025","article-title":"Use of reverse genetics to enhance the oncolytic properties of Newcastle disease virus","volume":"67","author":"Vigil","year":"2007","journal-title":"Cancer Res"},{"issue":"1","key":"key20211118215450_JCTH-D-21-00284-b23","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1128\/JVI.00401-09","article-title":"The oncolytic activity of Newcastle disease virus NDV-HUJ on chemoresistant primary melanoma cells is dependent on the proapoptotic activity of the inhibitor of apoptosis protein Livin","volume":"84","author":"Lazar","year":"2010","journal-title":"J Virol"},{"issue":"2","key":"key20211118215450_JCTH-D-21-00284-b24","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/mt.2009.231","article-title":"Engineered Newcastle disease virus as an improved oncolytic agent against hepatocellular carcinoma","volume":"18","author":"Altomonte","year":"2010","journal-title":"Mol Ther"},{"key":"key20211118215450_JCTH-D-21-00284-b25","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.omto.2019.03.004","article-title":"Fludarabine as an adjuvant improves Newcastle Disease Virus-mediated antitumor immunity in hepatocellular carcinoma","volume":"13","author":"Meng","year":"2019","journal-title":"Mol Ther Oncolytics"},{"key":"key20211118215450_JCTH-D-21-00284-b26","doi-asserted-by":"crossref","first-page":"e9761","DOI":"10.7717\/peerj.9761","article-title":"Oncolytic effects of the recombinant Newcastle disease virus, rAF-IL12, against colon cancer cells in vitro and in tumor-challenged NCr-Foxn1nu nude mice","volume":"8","author":"Syed Najmuddin","year":"2020","journal-title":"Peer J"},{"issue":"12","key":"key20211118215450_JCTH-D-21-00284-b27","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.3390\/cancers12123552","article-title":"Newcastle disease virus at the forefront of cancer immunotherapy","volume":"12","author":"Burman","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"3","key":"key20211118215450_JCTH-D-21-00284-b28","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/BF00184874","article-title":"Adjuvant treatment of locally advanced renal cancer with autologous virus-modified tumor vaccines","volume":"13","author":"Kirchner","year":"1995","journal-title":"World J Urol"},{"issue":"226","key":"key20211118215450_JCTH-D-21-00284-b29","doi-asserted-by":"crossref","first-page":"226ra32","DOI":"10.1126\/scitranslmed.3008095","article-title":"Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy","volume":"6","author":"Zamarin","year":"2014","journal-title":"Sci Transl Med"},{"issue":"1","key":"key20211118215450_JCTH-D-21-00284-b30","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/s41416-019-0639-7","article-title":"Targeting aerobic glycolysis by dichloroacetate improves Newcastle disease virus-mediated viro-immunotherapy in hepatocellular carcinoma","volume":"122","author":"Meng","year":"2020","journal-title":"Br J Cancer"},{"key":"key20211118215450_JCTH-D-21-00284-b31","first-page":"49","article-title":"Therapeutic potential of oncolytic Newcastle disease virus: a critical review","volume":"4","author":"Tayeb","year":"2015","journal-title":"Oncolytic Virother"},{"issue":"1","key":"key20211118215450_JCTH-D-21-00284-b32","doi-asserted-by":"crossref","first-page":"13999","DOI":"10.1038\/s41598-019-50222-z","article-title":"Evaluation of a Recombinant Newcastle Disease Virus Expressing Human IL12 against Human Breast Cancer","volume":"9","author":"Mohamed Amin","year":"2019","journal-title":"Sci Rep"},{"issue":"2","key":"key20211118215450_JCTH-D-21-00284-b33","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1134\/S0026893315020028","article-title":"Expressing foreign genes by Newcastle disease virus for cancer therapy","volume":"49","author":"Bai","year":"2015","journal-title":"Mol Biol (Mosk)"},{"issue":"1","key":"key20211118215450_JCTH-D-21-00284-b34","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3390\/biomedicines4010003","article-title":"In vitro synergistic enhancement of Newcastle disease virus to 5-fluorouracil cytotoxicity against tumor cells","volume":"4","author":"Al-Shammari","year":"2016","journal-title":"Biomedicines"},{"issue":"6","key":"key20211118215450_JCTH-D-21-00284-b35","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/j.immuni.2014.05.007","article-title":"Antiviral activity of human OASL protein is mediated by enhancing signaling of the RIG-I RNA sensor","volume":"40","author":"Zhu","year":"2014","journal-title":"Immunity"},{"key":"key20211118215450_JCTH-D-21-00284-b36","doi-asserted-by":"crossref","first-page":"649326","DOI":"10.3389\/fmed.2021.649326","article-title":"Three immune-related prognostic mRNAs as therapeutic targets for pancreatic cancer","volume":"8","author":"Zhang","year":"2021","journal-title":"Front Med (Lausanne)"},{"issue":"5","key":"key20211118215450_JCTH-D-21-00284-b37","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/mc.20807","article-title":"XIAP-associated factor 1 (XAF1), a novel target of p53, enhances p53-mediated apoptosis via post-translational modification","volume":"51","author":"Zou","year":"2012","journal-title":"Mol Carcinog"},{"issue":"9","key":"key20211118215450_JCTH-D-21-00284-b38","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1093\/carcin\/bgp155","article-title":"Identification of XAF1 as a novel cell cycle regulator through modulating G(2)\/M checkpoint and interaction with checkpoint kinase 1 in gastrointestinal cancer","volume":"30","author":"Wang","year":"2009","journal-title":"Carcinogenesis"},{"issue":"2","key":"key20211118215450_JCTH-D-21-00284-b39","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1158\/1538-7445.AM2011-170","article-title":"The XAF1 tumor suppressor induces autophagic cell death via upregulation of Beclin-1 and inhibition of Akt pathway","volume":"310","author":"Sun","year":"2011","journal-title":"Cancer Lett"},{"issue":"7","key":"key20211118215450_JCTH-D-21-00284-b40","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/s41579-018-0020-5","article-title":"ISG15 in antiviral immunity and beyond","volume":"16","author":"Perng","year":"2018","journal-title":"Nat Rev Microbiol"},{"issue":"12","key":"key20211118215450_JCTH-D-21-00284-b41","doi-asserted-by":"crossref","first-page":"e1052935","DOI":"10.1080\/2162402X.2015.1052935","article-title":"ISG15: A double edged sword in cancer","volume":"4","author":"Desai","year":"2015","journal-title":"Oncoimmunology"},{"issue":"1","key":"key20211118215450_JCTH-D-21-00284-b42","doi-asserted-by":"crossref","first-page":"e1003124","DOI":"10.1371\/journal.ppat.1003124","article-title":"IFITM proteins restrict viral membrane hemifusion","volume":"9","author":"Li","year":"2013","journal-title":"PLoS Pathog"},{"issue":"8","key":"key20211118215450_JCTH-D-21-00284-b43","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1080\/09168451.2020.1762479","article-title":"Knockdown of interferon-induced transmembrane protein 1 inhibited proliferation, induced cell cycle arrest and apoptosis, and suppressed MAPK signaling pathway in pancreatic cancer cells","volume":"84","author":"Zhang","year":"2020","journal-title":"Biosci Biotechnol Biochem"},{"issue":"5","key":"key20211118215450_JCTH-D-21-00284-b44","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.1073\/pnas.052430399","article-title":"Antivirally active MxA protein sequesters La Crosse virus nucleocapsid protein into perinuclear complexes","volume":"99","author":"Kochs","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7297","key":"key20211118215450_JCTH-D-21-00284-b45","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/nature08972","article-title":"Structural basis of oligomerization in the stalk region of dynamin-like MxA","volume":"465","author":"Gao","year":"2010","journal-title":"Nature"},{"issue":"6","key":"key20211118215450_JCTH-D-21-00284-b46","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/gene.2011.21","article-title":"IRF7: activation, regulation, modification and function","volume":"12","author":"Ning","year":"2011","journal-title":"Genes Immun"},{"issue":"21","key":"key20211118215450_JCTH-D-21-00284-b47","doi-asserted-by":"crossref","first-page":"10576","DOI":"10.1158\/0008-5472.CAN-06-1279","article-title":"Distinct roles for IFN regulatory factor (IRF)-3 and IRF-7 in the activation of antitumor properties of human macrophages","volume":"66","author":"Romieu-Mourez","year":"2006","journal-title":"Cancer Res"},{"issue":"8","key":"key20211118215450_JCTH-D-21-00284-b48","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1089\/jir.2007.0021","article-title":"Antiproliferative activity of the human IFN-alpha-inducible protein IFI44","volume":"27","author":"Hallen","year":"2007","journal-title":"J Interferon Cytokine Res"},{"issue":"7373","key":"key20211118215450_JCTH-D-21-00284-b49","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/nature10537","article-title":"Structural basis of RNA recognition and activation by innate immune receptor RIG-I","volume":"479","author":"Jiang","year":"2011","journal-title":"Nature"},{"issue":"4","key":"key20211118215450_JCTH-D-21-00284-b50","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.3892\/ijo.2015.2853","article-title":"RIG-I suppresses the migration and invasion of hepatocellular carcinoma cells by regulating MMP9","volume":"46","author":"Liu","year":"2015","journal-title":"Int J Oncol"},{"issue":"2","key":"key20211118215450_JCTH-D-21-00284-b51","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/ijc.21821","article-title":"Tumor selective replication of Newcastle disease virus: association with defects of tumor cells in antiviral defence","volume":"119","author":"Fiola","year":"2006","journal-title":"Int J Cancer"},{"issue":"7470","key":"key20211118215450_JCTH-D-21-00284-b52","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/nature12515","article-title":"The genesis and source of the H7N9 influenza viruses causing human infections in China","volume":"502","author":"Lam","year":"2013","journal-title":"Nature"},{"issue":"10","key":"key20211118215450_JCTH-D-21-00284-b53","first-page":"5401","article-title":"Sensitivity of human malignant melanoma cell Lines to Newcastle disease virus","volume":"35","author":"Pap","year":"2015","journal-title":"Anticancer Res"},{"issue":"4","key":"key20211118215450_JCTH-D-21-00284-b54","doi-asserted-by":"crossref","first-page":"e0195425","DOI":"10.1371\/journal.pone.0195425","article-title":"Oncolytic effect of wild-type Newcastle disease virus isolates in cancer cell lines in vitro and in vivo on xenograft model","volume":"13","author":"Yurchenko","year":"2018","journal-title":"PLoS One"},{"issue":"4","key":"key20211118215450_JCTH-D-21-00284-b55","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.immuni.2012.03.013","article-title":"The JAK-STAT pathway at twenty","volume":"36","author":"Stark","year":"2012","journal-title":"Immunity"},{"issue":"7","key":"key20211118215450_JCTH-D-21-00284-b56","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/nri3845","article-title":"Type I interferons in anticancer immunity","volume":"15","author":"Zitvogel","year":"2015","journal-title":"Nat Rev Immunol"}],"container-title":["Journal of Clinical and Translational Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.xiahepublishing.com\/2310-8819\/JCTH-2021-00284","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T18:20:44Z","timestamp":1783707644000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.xiahepublishing.com\/2310-8819\/JCTH-2021-00284"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,19]]},"references-count":56,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,3,2]]},"published-print":{"date-parts":[[2022,4,28]]}},"alternative-id":["10.14218\/JCTH.2021.00284"],"URL":"https:\/\/doi.org\/10.14218\/jcth.2021.00284","relation":{},"ISSN":["2225-0719","2310-8819"],"issn-type":[{"value":"2225-0719","type":"print"},{"value":"2310-8819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,19]]}}}